Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for tags : Vaccine save search
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
EVAX | $4.08 -2.63% -2.7% 25K
|
Manufacturing
|
| O: 6.58%
H: 14.71%
C: 14.12%
vaccine infection results
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.63%
pneumococcal vaccine merck positive
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -0.81%
gardasil vaccine merck trials
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Published: 2024-03-05 (Crawled : 07:00) - globenewswire.com
NIPNF | $66.9 -52.94% 140
|
Technology Services
| Email alert
Add to watchlist
tg4050 vaccine cancer collaboration trial
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Published: 2024-01-24 (Crawled : 14:30) - globenewswire.com
CAPR | $4.81 -2.63% -2.7% 480K
|
Health Technology
|
| O: 2.18%
H: 6.4%
C: -3.32%
vaccine sars-cov-2 collaboration trial therapeutics
CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL
Published: 2024-01-22 (Crawled : 18:00) - prnewswire.com
OVV | $52.77 1.13% 0.0% 1.6M
|
Energy Minerals
|
| O: -0.49%
H: 1.94%
C: 1.42%
covid19 corbevax vaccine health world approval hospital protein technology
Global Respiratory Disease Vaccine Market Set for Growth, Fueled by Aging Populations and Vaccine Mandates - Trends, Opportunities, and Forecasts, 2018-2028F
Published: 2024-01-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: -0.15%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 2.63%
H: 0.8%
C: 0.75%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 1.8%
H: 0.14%
C: -0.89%
disease vaccine respiratory global set market
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Published: 2024-01-19 (Crawled : 13:30) - globenewswire.com
VXRT | News | $0.7422 -2.66% -2.74% 1.5M
|
Health Technology
|
| O: 2.1%
H: 1.04%
C: -8.52%
covid-19 award candidate vaccine million nextgen study
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
HLVX | $12.8 -1.39% -1.41% 160K
|
|
| O: 0.72%
H: 2.22%
C: 0.33%
candidate vaccine license norovirus agreement china
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
Published: 2023-12-18 (Crawled : 13:00) - globenewswire.com
PVCT 4 | $0.1948 -15.0% 63K
|
Manufacturing
|
| O: 0.0%
H: 0.73%
C: -15.5%
first patent rose antiviral vaccine
Influenza Vaccine Market to grow by USD 2.93 billion from 2022 to 2027; North America to account for 54% of market growth - Technavio
Published: 2023-12-13 (Crawled : 19:00) - prnewswire.com
CMXHF | $176.0 -19.21% 50
|
n/a
|
| O: 5.56%
H: 0.71%
C: 0.71%
CSLLY | $89.17 3.3% 54K
|
n/a
|
| O: 1.46%
H: 3.01%
C: 0.97%
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: -1.01%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 1.19%
H: 3.09%
C: 1.3%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.76%
H: 1.0%
C: -0.11%
BAX | $41.02 1.54% 0.0% 2.6M
|
Health Technology
|
| O: 1.7%
H: 2.44%
C: 1.78%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 1.21%
H: 0.27%
C: -0.52%
america vaccine influenza growth market
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Published: 2023-12-12 (Crawled : 07:00) - globenewswire.com
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 53.48%
H: 1.02%
C: 0.26%
candidate vaccine positive topline rsv results
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.24%
H: 1.34%
C: -0.41%
vla15 disease vaccine valneva trial
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Published: 2023-11-29 (Crawled : 13:30) - globenewswire.com
DYAI 4 | $1.5 -1.96% -2.0% 8.8K
|
Health Technology
|
| O: -0.85%
H: 5.71%
C: -2.29%
candidate vaccine trial results
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Published: 2023-11-28 (Crawled : 13:00) - prnewswire.com
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
|
| O: -3.42%
H: 3.24%
C: 2.95%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: -0.93%
arct-154 covid vaccine approved mrna
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
Published: 2023-11-28 (Crawled : 11:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 1.1%
H: 5.07%
C: 3.8%
covid-19 vaccine health world
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
Published: 2023-11-27 (Crawled : 21:00) - globenewswire.com
PPRUF | News | $364.27 37.56% 850
|
Consumer Non-Durables
|
| O: -1.83%
H: 1.83%
C: -2.33%
PPRUY | News | $36.96 -0.11% 220K
|
Manufacturing
|
| O: -2.83%
H: 1.05%
C: 0.51%
PCVX | $60.89 -1.15% -1.17% 670K
|
Health Technology
|
| O: -1.82%
H: 1.91%
C: 1.75%
STRO | $3.73 -1.06% -1.07% 720K
|
Health Technology
|
| O: 6.14%
H: 1.24%
C: -5.79%
vaccine control biopharma agreement
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
PVCT 4 | $0.1948 -15.0% 63K
|
Manufacturing
|
| O: 0.46%
H: 7.31%
C: 6.85%
pv-10 vaccine presentation cancer preclinical immunotherapy meeting
Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 4.1%
H: 0.0%
C: -1.96%
tnx-1800 vaccine nextgen trials
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
Published: 2023-10-30 (Crawled : 13:00) - globenewswire.com
GOVX | $1.57 1.29% 1.27% 32K
|
Health Technology
|
| O: 0.0%
H: 2.02%
C: -1.42%
covid-19 vaccine expansion trial phase 2
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.